...
首页> 外文期刊>Experimental and therapeutic medicine >Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
【24h】

Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals

机译:非布司他在空腹条件下在健康个体中的药代动力学和药效学

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to investigate the pharmacokinetic and pharmacodynamic characteristics of febuxostat following the administration of single and multiple oral doses under fasting conditions to healthy individuals. Thirty-six healthy subjects were randomly divided into three groups, each containing 12 subjects (six male and six female) as follows: Group A, treated with a single oral dose of febuxostat (40 mg); group B, treated with a single oral dose of febuxostat (80 mg) followed by multiple oral doses of febuxostat for 7 days; and group C, treated with a single oral dose of febuxostat (120 mg). Blood samples were collected, and the plasma drug levels and serum uric acid (UA) concentrations were determined by clinical laboratory testing. Febuxostat displayed a linear pharmacokinetic profile for oral doses of 40 to 120 mg. Drug accumulation was not detected following multiple oral doses. When febuxostat was administered as single doses of 40, 80 and 120 mg, the 24-h UA concentration (UA24) values displayed a linear correlation with the dosage. The relationship between UA24 and the three single dose levels (40, 80 and 120 mg) was analyzed. The difference in UA24 between every single dose was significant (P<0.05). After 3 and 7 days of dosing, reductions of 46.67 and 52.69%, respectively, were observed in UA24. On day 7 of dosing, the mean reduction in the UA concentration was 51.83±7.00%. This study demonstrates that febuxostat reduces serum UA concentrations in a dose-linear manner.
机译:本研究的目的是研究在禁食条件下向健康个体施用单次或多次口服剂量后,非布索坦的药代动力学和药效动力学特性。将36名健康受试者随机分为三组,每组包括12名受试者(六名男性和六名女性),如下所述:A组,单次口服非布索坦治疗(40 mg); B组,单次口服非布索坦(80 mg),然后多次口服非布索坦7天; C组,单次口服非布索坦(120 mg)治疗。收集血样,并通过临床实验室测试确定血浆药物水平和血清尿酸(UA)浓度。非布索坦口服剂量为40至120 mg时显示出线性药物动力学曲线。多次口服后未发现药物蓄积。当非布索坦以40、80和120 mg单剂量给药时,其24小时UA浓度(UA24)值与该剂量呈线性关系。分析了UA24和三个单剂量水平(40、80和120 mg)之间的关系。每个单剂量之间的UA24差异显着(P <0.05)。给药3天和7天后,UA24分别降低了46.67%和52.69%。给药第7天,UA浓度的平均降低为51.83±7.00%。这项研究表明非布索坦以剂量线性方式降低血清UA浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号